- Motley Fool•6 hours ago
Despite a rising market, these stocks fell. Find out why.
- Reuters•8 hours ago
Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve all global patent-infringement litigation related to its cancer drug, Keytruda. Merck will make an initial payment of $625 million to Bristol and Japan's Ono. The company will also pay a 6.5 percent royalty rate on Keytruda sales from January 2017 to December 2023, and a 2.5 percent rate for the subsequent three years.
- Barrons.com•8 hours ago
Bristol-Myers Squibb (BMY) tumbled to the bottom of the S&P 500 today after the company said it would not try to get a quick approval from the FDA for its lung cancer treatment. Bristol-Myers Squibb dropped 11% to $49.23, while the S&P 500 advanced 0.3% to 2,271.31. Morgan Stanley's David Risinger and team call is a "perplexing disappointment." They explain why: Negative signal about the profile of combo in lung cancer.
BMY : Summary for Bristol-Myers Squibb Company Co - Yahoo Finance
Bristol-Myers Squibb Company (BMY)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||48.92 - 50.69|
|52 Week Range||48.92 - 77.12|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||24.63|
|Dividend & Yield||1.56 (2.78%)|
|1y Target Est||N/A|